Narrative review / 2017
A review notes that unlike preclinical studies, human studies show resveratrol cannot protect against metabolic diseases and associated complications.
This review evaluates preclinical and clinical findings on the dietary polyphenol resveratrol regarding its dose, absorption, interactions, toxicity, and therapeutic effects against chronic conditions. A comparison of animal and human studies indicates that resveratrol cannot protect against metabolic diseases and their related complications. The authors note that clinical outcomes are influenced by factors such as sample size.
- Study type
- Narrative review
- Who was studied
- Human and animal studies
- What was measured
- Metabolic and chronic disease outcomes, dose, absorption, and toxicity
THE PAPER
Significance of Resveratrol in Clinical Management of Chronic Diseases.
Wahab A, Gao K, Jia C, Zhang F, Tian G, Murtaza G, Chen J. Molecules, 2017.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.